Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

According to a new poll, the subject appears to be less controversial than the loud minority would have us believe.

A new multi-state study led by the Centers for Disease Control and Prevention's (CDC) VISION Network—including Regenstrief ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

More information: Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults, JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2025.17402 ...